Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease

Clifford R Jr. Jack, Frederik Barkhof, Matthew A Bernstein, Marc Cantillon, Patricia E. Cole, Charles Decarli, Bruno Dubois, Simon Duchesne, Nick C. Fox, Giovanni B. Frisoni, Harald Hampel, Derek L G Hill, Keith Johnson, Jean Franois Mangin, Philip Scheltens, Adam J. Schwarz, Reisa Sperling, Joyce Suhy, Paul M. Thompson, Michael WeinerNorman L. Foster

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Background: The promise of Alzheimer's disease biomarkers has led to their incorporation in new diagnostic criteria and in therapeutic trials; however, significant barriers exist to widespread use. Chief among these is the lack of internationally accepted standards for quantitative metrics. Hippocampal volumetry is the most widely studied quantitative magnetic resonance imaging measure in Alzheimer's disease and thus represents the most rational target for an initial effort at standardization. Methods and Results: The authors of this position paper propose a path toward this goal. The steps include the following: (1) Establish and empower an oversight board to manage and assess the effort, (2) adopt the standardized definition of anatomic hippocampal boundaries on magnetic resonance imaging arising from the European Alzheimer's Disease Centers-Alzheimer's Disease Neuroimaging Initiative hippocampal harmonization effort as a reference standard, (3) establish a scientifically appropriate, publicly available reference standard data set based on manual delineation of the hippocampus in an appropriate sample of subjects (Alzheimer's Disease Neuroimaging Initiative), and (4) define minimum technical and prognostic performance metrics for validation of new measurement techniques using the reference standard data set as a benchmark. Conclusions: Although manual delineation of the hippocampus is the best available reference standard, practical application of hippocampal volumetry will require automated methods. Our intent was to establish a mechanism for credentialing automated software applications to achieve internationally recognized accuracy and prognostic performance standards that lead to the systematic evaluation and then widespread acceptance and use of hippocampal volumetry. The standardization and assay validation process outlined for hippocampal volumetry was envisioned as a template that could be applied to other imaging biomarkers.

Original languageEnglish (US)
JournalAlzheimer's and Dementia
Volume7
Issue number4
DOIs
StatePublished - Jul 2011

Fingerprint

Alzheimer Disease
Biomarkers
Clinical Trials
Neuroimaging
Hippocampus
Magnetic Resonance Imaging
Credentialing
Benchmarking
Software

Keywords

  • Alzheimer's disease
  • Biomarker standards
  • Biomarkers
  • Hippocampus
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. / Jack, Clifford R Jr.; Barkhof, Frederik; Bernstein, Matthew A; Cantillon, Marc; Cole, Patricia E.; Decarli, Charles; Dubois, Bruno; Duchesne, Simon; Fox, Nick C.; Frisoni, Giovanni B.; Hampel, Harald; Hill, Derek L G; Johnson, Keith; Mangin, Jean Franois; Scheltens, Philip; Schwarz, Adam J.; Sperling, Reisa; Suhy, Joyce; Thompson, Paul M.; Weiner, Michael; Foster, Norman L.

In: Alzheimer's and Dementia, Vol. 7, No. 4, 07.2011.

Research output: Contribution to journalArticle

Jack, CRJ, Barkhof, F, Bernstein, MA, Cantillon, M, Cole, PE, Decarli, C, Dubois, B, Duchesne, S, Fox, NC, Frisoni, GB, Hampel, H, Hill, DLG, Johnson, K, Mangin, JF, Scheltens, P, Schwarz, AJ, Sperling, R, Suhy, J, Thompson, PM, Weiner, M & Foster, NL 2011, 'Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease', Alzheimer's and Dementia, vol. 7, no. 4. https://doi.org/10.1016/j.jalz.2011.04.007
Jack, Clifford R Jr. ; Barkhof, Frederik ; Bernstein, Matthew A ; Cantillon, Marc ; Cole, Patricia E. ; Decarli, Charles ; Dubois, Bruno ; Duchesne, Simon ; Fox, Nick C. ; Frisoni, Giovanni B. ; Hampel, Harald ; Hill, Derek L G ; Johnson, Keith ; Mangin, Jean Franois ; Scheltens, Philip ; Schwarz, Adam J. ; Sperling, Reisa ; Suhy, Joyce ; Thompson, Paul M. ; Weiner, Michael ; Foster, Norman L. / Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. In: Alzheimer's and Dementia. 2011 ; Vol. 7, No. 4.
@article{cddff550b0a64d1fa64771f60ac7f189,
title = "Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease",
abstract = "Background: The promise of Alzheimer's disease biomarkers has led to their incorporation in new diagnostic criteria and in therapeutic trials; however, significant barriers exist to widespread use. Chief among these is the lack of internationally accepted standards for quantitative metrics. Hippocampal volumetry is the most widely studied quantitative magnetic resonance imaging measure in Alzheimer's disease and thus represents the most rational target for an initial effort at standardization. Methods and Results: The authors of this position paper propose a path toward this goal. The steps include the following: (1) Establish and empower an oversight board to manage and assess the effort, (2) adopt the standardized definition of anatomic hippocampal boundaries on magnetic resonance imaging arising from the European Alzheimer's Disease Centers-Alzheimer's Disease Neuroimaging Initiative hippocampal harmonization effort as a reference standard, (3) establish a scientifically appropriate, publicly available reference standard data set based on manual delineation of the hippocampus in an appropriate sample of subjects (Alzheimer's Disease Neuroimaging Initiative), and (4) define minimum technical and prognostic performance metrics for validation of new measurement techniques using the reference standard data set as a benchmark. Conclusions: Although manual delineation of the hippocampus is the best available reference standard, practical application of hippocampal volumetry will require automated methods. Our intent was to establish a mechanism for credentialing automated software applications to achieve internationally recognized accuracy and prognostic performance standards that lead to the systematic evaluation and then widespread acceptance and use of hippocampal volumetry. The standardization and assay validation process outlined for hippocampal volumetry was envisioned as a template that could be applied to other imaging biomarkers.",
keywords = "Alzheimer's disease, Biomarker standards, Biomarkers, Hippocampus, Magnetic resonance imaging",
author = "Jack, {Clifford R Jr.} and Frederik Barkhof and Bernstein, {Matthew A} and Marc Cantillon and Cole, {Patricia E.} and Charles Decarli and Bruno Dubois and Simon Duchesne and Fox, {Nick C.} and Frisoni, {Giovanni B.} and Harald Hampel and Hill, {Derek L G} and Keith Johnson and Mangin, {Jean Franois} and Philip Scheltens and Schwarz, {Adam J.} and Reisa Sperling and Joyce Suhy and Thompson, {Paul M.} and Michael Weiner and Foster, {Norman L.}",
year = "2011",
month = "7",
doi = "10.1016/j.jalz.2011.04.007",
language = "English (US)",
volume = "7",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease

AU - Jack, Clifford R Jr.

AU - Barkhof, Frederik

AU - Bernstein, Matthew A

AU - Cantillon, Marc

AU - Cole, Patricia E.

AU - Decarli, Charles

AU - Dubois, Bruno

AU - Duchesne, Simon

AU - Fox, Nick C.

AU - Frisoni, Giovanni B.

AU - Hampel, Harald

AU - Hill, Derek L G

AU - Johnson, Keith

AU - Mangin, Jean Franois

AU - Scheltens, Philip

AU - Schwarz, Adam J.

AU - Sperling, Reisa

AU - Suhy, Joyce

AU - Thompson, Paul M.

AU - Weiner, Michael

AU - Foster, Norman L.

PY - 2011/7

Y1 - 2011/7

N2 - Background: The promise of Alzheimer's disease biomarkers has led to their incorporation in new diagnostic criteria and in therapeutic trials; however, significant barriers exist to widespread use. Chief among these is the lack of internationally accepted standards for quantitative metrics. Hippocampal volumetry is the most widely studied quantitative magnetic resonance imaging measure in Alzheimer's disease and thus represents the most rational target for an initial effort at standardization. Methods and Results: The authors of this position paper propose a path toward this goal. The steps include the following: (1) Establish and empower an oversight board to manage and assess the effort, (2) adopt the standardized definition of anatomic hippocampal boundaries on magnetic resonance imaging arising from the European Alzheimer's Disease Centers-Alzheimer's Disease Neuroimaging Initiative hippocampal harmonization effort as a reference standard, (3) establish a scientifically appropriate, publicly available reference standard data set based on manual delineation of the hippocampus in an appropriate sample of subjects (Alzheimer's Disease Neuroimaging Initiative), and (4) define minimum technical and prognostic performance metrics for validation of new measurement techniques using the reference standard data set as a benchmark. Conclusions: Although manual delineation of the hippocampus is the best available reference standard, practical application of hippocampal volumetry will require automated methods. Our intent was to establish a mechanism for credentialing automated software applications to achieve internationally recognized accuracy and prognostic performance standards that lead to the systematic evaluation and then widespread acceptance and use of hippocampal volumetry. The standardization and assay validation process outlined for hippocampal volumetry was envisioned as a template that could be applied to other imaging biomarkers.

AB - Background: The promise of Alzheimer's disease biomarkers has led to their incorporation in new diagnostic criteria and in therapeutic trials; however, significant barriers exist to widespread use. Chief among these is the lack of internationally accepted standards for quantitative metrics. Hippocampal volumetry is the most widely studied quantitative magnetic resonance imaging measure in Alzheimer's disease and thus represents the most rational target for an initial effort at standardization. Methods and Results: The authors of this position paper propose a path toward this goal. The steps include the following: (1) Establish and empower an oversight board to manage and assess the effort, (2) adopt the standardized definition of anatomic hippocampal boundaries on magnetic resonance imaging arising from the European Alzheimer's Disease Centers-Alzheimer's Disease Neuroimaging Initiative hippocampal harmonization effort as a reference standard, (3) establish a scientifically appropriate, publicly available reference standard data set based on manual delineation of the hippocampus in an appropriate sample of subjects (Alzheimer's Disease Neuroimaging Initiative), and (4) define minimum technical and prognostic performance metrics for validation of new measurement techniques using the reference standard data set as a benchmark. Conclusions: Although manual delineation of the hippocampus is the best available reference standard, practical application of hippocampal volumetry will require automated methods. Our intent was to establish a mechanism for credentialing automated software applications to achieve internationally recognized accuracy and prognostic performance standards that lead to the systematic evaluation and then widespread acceptance and use of hippocampal volumetry. The standardization and assay validation process outlined for hippocampal volumetry was envisioned as a template that could be applied to other imaging biomarkers.

KW - Alzheimer's disease

KW - Biomarker standards

KW - Biomarkers

KW - Hippocampus

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=79960830268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960830268&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2011.04.007

DO - 10.1016/j.jalz.2011.04.007

M3 - Article

C2 - 21784356

AN - SCOPUS:79960830268

VL - 7

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 4

ER -